Background: Transplantation of pancreatic β-cells generated from human induced pluripotent stem cells (hiPSCs) has great potential as a root treatment for type 1 diabetes. However, their current level of efficiency to differentiate into β-cells is still not at par for clinical use. Previous research has shown that differentiation efficiency varies among human embryonic stem cells and mouse-induced pluripotent stem cell lines. Therefore, selecting a suitable cell line for efficient induction into desired tissues and organs is crucial. Method: In this study, we have evaluated the efficiency of 15 hiPSC lines available for clinical use to differentiate into pancreatic β-cells. Results: Our investigation has revealed induction efficiency to differ among the hiPSC lines, even when derived from the same donor. Among the hiPSC lines tested, the 16A01 cell line exhibited the highest insulin expression and low glucagon expression, suggesting that this cell line is suitable for differentiation into β-cells. Conclusion: Our study has demonstrated the importance of selecting a suitable hiPSC line for effective differentiation into β-cells.

中文翻译：

---

临床使用的人 iPSC 系的胰腺 β 细胞分化效率评估

背景：移植由人类诱导多能干细胞 (hiPSC) 产生的胰腺 β 细胞作为 1 型糖尿病的根本治疗具有巨大潜力。然而，它们目前分化为β细胞的效率水平仍达不到临床应用的水平。先前的研究表明，人类胚胎干细胞和小鼠诱导的多能干细胞系的分化效率存在差异。因此，选择合适的细胞系来有效诱导所需的组织和器官至关重要。方法：在本研究中，我们评估了 15 个可供临床使用的 hiPSC 系分化为胰腺 β 细胞的效率。结果：我们的研究表明，即使来自同一供体，hiPSC 系的诱导效率也存在差异。在测试的 hiPSC 系中，16A01 细胞系表现出最高的胰岛素表达和较低的胰高血糖素表达，表明该细胞系适合分化为 β 细胞。结论：我们的研究证明了选择合适的 hiPSC 系对于有效分化为 β 细胞的重要性。